CUE vs. VTVT, ASMB, CRVS, CARM, DERM, YS, HOOK, TPST, ANEB, and CNTB
Should you be buying Cue Biopharma stock or one of its competitors? The main competitors of Cue Biopharma include vTv Therapeutics (VTVT), Assembly Biosciences (ASMB), Corvus Pharmaceuticals (CRVS), Carisma Therapeutics (CARM), Journey Medical (DERM), YS Biopharma (YS), Hookipa Pharma (HOOK), Tempest Therapeutics (TPST), Anebulo Pharmaceuticals (ANEB), and Connect Biopharma (CNTB). These companies are all part of the "pharmaceutical preparations" industry.
vTv Therapeutics (NASDAQ:VTVT) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, dividends, valuation and risk.
vTv Therapeutics has a net margin of 0.00% compared to vTv Therapeutics' net margin of -924.10%. Cue Biopharma's return on equity of 0.00% beat vTv Therapeutics' return on equity.
vTv Therapeutics received 208 more outperform votes than Cue Biopharma when rated by MarketBeat users. Likewise, 57.83% of users gave vTv Therapeutics an outperform vote while only 51.81% of users gave Cue Biopharma an outperform vote.
vTv Therapeutics has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500.
vTv Therapeutics has higher earnings, but lower revenue than Cue Biopharma. vTv Therapeutics is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cue Biopharma had 2 more articles in the media than vTv Therapeutics. MarketBeat recorded 2 mentions for Cue Biopharma and 0 mentions for vTv Therapeutics. Cue Biopharma's average media sentiment score of 1.05 beat vTv Therapeutics' score of -0.33 indicating that vTv Therapeutics is being referred to more favorably in the media.
17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 1.7% of vTv Therapeutics shares are held by insiders. Comparatively, 10.2% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Cue Biopharma has a consensus target price of $8.00, suggesting a potential upside of 483.94%. Given vTv Therapeutics' higher probable upside, analysts plainly believe Cue Biopharma is more favorable than vTv Therapeutics.
Summary
Cue Biopharma beats vTv Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Cue Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cue Biopharma Competitors List
Related Companies and Tools
